White Paper

Human Factors Considerations For Combination Products

By Ana Ladino

Human Factors Considerations For Combination Products

In February of 2016, the FDA released a draft guidance regarding Human Factors and Related Clinical Study Considerations in Combination Product Design and Development. This paper highlights the human factors studies in the development in combination products, clarifies the difference between the studies, and discusses how the studies are part of the process to maximize the likelihood that the combination product user interface is safe and effective for use by the intended users, uses, and environments.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development

West Pharmaceutical Services, Inc.